Innovative therapeutics

Investors

NASDAQBMRN
FormDescriptionDateFormat
SC 13G/AAmendment to a previously filed SC 13GSep 8, 2005View HTMLDownload DOCDownload PDFDownload XLS
UPLOADCorrespondence from the SEC to the FilerJul 14, 2005View HTMLDownload DOCDownload PDF
UPLOADCorrespondence from the SEC to the FilerJul 14, 2005View HTMLDownload DOCDownload PDF
UPLOADCorrespondence from the SEC to the FilerJul 14, 2005View HTMLDownload DOCDownload PDF
UPLOADCorrespondence from the SEC to the FilerJul 11, 2005View HTMLDownload DOCDownload PDF
UPLOADCorrespondence from the SEC to the FilerJul 11, 2005View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GJun 27, 2005View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsJun 10, 2005View HTMLDownload DOCDownload PDF
SC 13D/AAmendment to a SC 13D filingJun 6, 2005View HTMLDownload DOCDownload PDFDownload XLS
CORRESPCorrespondence from the Filer to the SECMay 19, 2005View HTMLDownload DOCDownload PDFDownload XLS
CORRESPCorrespondence from the Filer to the SECMay 16, 2005View HTMLDownload DOCDownload PDFDownload XLS
SC 13D/AAmendment to a SC 13D filingMay 6, 2005View HTMLDownload DOCDownload PDFDownload XLS
SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%Apr 15, 2005View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GMar 31, 2005View HTMLDownload DOCDownload PDFDownload XLS
NO ACTNo Action LettersMar 9, 2005View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2005View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 14, 2005View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 11, 2005View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 10, 2005View HTMLDownload DOCDownload PDFDownload XLS

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information